Under the leadership of Dr Mohammed Maniruzzaman, AMD is funding the development of a continuous manufacturing technique, in conjunction with co-crystal technology for improved drug absorption, with early scoping of future potential for 3D printing technology in personalised drug delivery. Future projects include “Portapill” as the world’s smallest 3D printer to print medicines on demand. This unit will be fully mobile to print medicines, vaccines and anti-biotics as required. We intend to engineer the printing inks which contain the drugs and designed to be stable in variable conditions. One interesting potential application has seen Dr Maniruzzaman recently selected by NASA as a panellist for “just in time medications” for in space projects.